[go: up one dir, main page]

WO2012037498A3 - Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo - Google Patents

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo Download PDF

Info

Publication number
WO2012037498A3
WO2012037498A3 PCT/US2011/052002 US2011052002W WO2012037498A3 WO 2012037498 A3 WO2012037498 A3 WO 2012037498A3 US 2011052002 W US2011052002 W US 2011052002W WO 2012037498 A3 WO2012037498 A3 WO 2012037498A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
herpesviral
heparan sulfate
vivo
herpes simplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/052002
Other languages
French (fr)
Other versions
WO2012037498A2 (en
Inventor
Deepak Shukla
Vaibhav Tiwari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois at Chicago
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois at Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois at Chicago filed Critical University of Illinois at Urbana Champaign
Priority to EP11826047.0A priority Critical patent/EP2616478A4/en
Publication of WO2012037498A2 publication Critical patent/WO2012037498A2/en
Publication of WO2012037498A3 publication Critical patent/WO2012037498A3/en
Priority to US13/842,193 priority patent/US20130189784A1/en
Anticipated expiration legal-status Critical
Priority to US14/555,000 priority patent/US9464113B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are anti-heparan sulfate peptides and methods that employ those peptides for the prevention or treatment of viral infections, including herpesviral infections such as α-herpesviral, β-herpesviral, and γ-herpesviral infections, which are exemplified by HSV-1. CMV, and HHV-8 viral infections, respectively. Peptides comprise at least 10 amino acids of the amino acid sequences XRXRXKXXRXRX and/or XXRRRRXRRRXK, wherein X represents any amino acid, which are exemplified by peptides that comprise at least 10 amino acids of the sequence LRSRTKIIRIRH and/or at least 10 amino acids of the sequence MPRRRRIRRRQK. Peptides may be coupled to one or more therapeutic compound(s) to generate peptide-therapeutic compound conjugates, wherein the therapeutic compound may be one or more of a nucleoside analog, an oligosaccharide, and a small molecule.
PCT/US2011/052002 2010-09-16 2011-09-16 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo Ceased WO2012037498A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11826047.0A EP2616478A4 (en) 2010-09-16 2011-09-16 ANTI-HEPARAN SULPHATE PEPTIDES BLOCKING HERPES SIMPLEX IN VIVO VIRUS INFECTION
US13/842,193 US20130189784A1 (en) 2010-09-16 2013-03-15 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo
US14/555,000 US9464113B2 (en) 2010-09-16 2014-11-26 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38352010P 2010-09-16 2010-09-16
US61/383,520 2010-09-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/842,193 Continuation-In-Part US20130189784A1 (en) 2010-09-16 2013-03-15 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Publications (2)

Publication Number Publication Date
WO2012037498A2 WO2012037498A2 (en) 2012-03-22
WO2012037498A3 true WO2012037498A3 (en) 2012-07-05

Family

ID=45832272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052002 Ceased WO2012037498A2 (en) 2010-09-16 2011-09-16 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Country Status (2)

Country Link
EP (1) EP2616478A4 (en)
WO (1) WO2012037498A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015102738A1 (en) * 2013-10-18 2015-07-09 The Charles Stark Draper Laboratory, Inc. Multivalent antiviral compositions, methods of making, and uses thereof
CN103788232A (en) * 2013-12-23 2014-05-14 深圳市海普瑞药业股份有限公司 Heparitin sulfate decasaccharide as well as preparation method and application thereof
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
EP3186273A4 (en) 2014-08-26 2018-05-02 University of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
US10702572B2 (en) * 2015-07-28 2020-07-07 Carnegie Mellon University Methods and compounds to suppress viral genome release and packaging
JP2024505000A (en) * 2021-01-27 2024-02-02 シーエスティーエス ヘルス ケア インク． Platelet alpha granules for delivery of multiple proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US20020119165A1 (en) * 1998-08-18 2002-08-29 Lambris John D. Peptides for inhibition of herpes simplex virus entry
US20060051368A1 (en) * 2004-07-23 2006-03-09 Northwestern University Herpes simplex virus mutations
US20090068215A1 (en) * 2007-07-05 2009-03-12 David Davido Herpes simplex virus mutant icp0 protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US20020119165A1 (en) * 1998-08-18 2002-08-29 Lambris John D. Peptides for inhibition of herpes simplex virus entry
US20060051368A1 (en) * 2004-07-23 2006-03-09 Northwestern University Herpes simplex virus mutations
US20090068215A1 (en) * 2007-07-05 2009-03-12 David Davido Herpes simplex virus mutant icp0 protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2616478A4 *
TIWARI, V. ET AL.: "Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo", J. BIOL. CHEM., vol. 286, no. 28, 15 July 2011 (2011-07-15), pages 25406 - 25415, XP055106690 *

Also Published As

Publication number Publication date
WO2012037498A2 (en) 2012-03-22
EP2616478A4 (en) 2014-04-23
EP2616478A2 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
WO2012037498A3 (en) Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
HK1203514A1 (en) D-amino acid compounds for liver disease
PH12013502141A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2009129470A3 (en) Methods for treating herpes virus infections
WO2009024585A3 (en) Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
WO2010029302A3 (en) Compounds for treating viral infections
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
MX2011007364A (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections.
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2010084115A3 (en) Antiviral agents
WO2008100447A3 (en) Nucleoside analogs for antiviral treatment
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
CA2753382C (en) Hepatitis c virus inhibitors
NZ604716A (en) 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
HK1203075A1 (en) Substituted phosphorothioate nucleotide analogs
PH12012502528A1 (en) Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
IN2014MN01547A (en)
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
HK1217295A1 (en) 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11826047

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011826047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011826047

Country of ref document: EP